Huadong Medicine Deal History & Licensing Activity
Huadong Medicine is a large biotech headquartered in Ireland. Over the past three years, Huadong Medicine has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (2 deals). The company currently has 18 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
2
Active Trials
18
Top Modality
Small Molecules
Focus Area
Solid Tumors
Huadong Medicine Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Huadong Medicine in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| roflumilast | Arcutis | Small Molecules | Unknown | license | Jul 2025 |
Huadong Medicine Pipeline Focus
Therapeutic areas and modalities where Huadong Medicine is most active based on deal history and clinical trial data.
Therapeutic Areas
Huadong Medicine Strategic Signals
Key indicators of Huadong Medicine's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Huadong Medicine Clinical Pipeline
Huadong Medicine has 18 active clinical trials across 4 development phases.
5
Unknown
7
Not Applicable
2
Phase 2
4
Phase 3
See How Your Asset Matches Huadong Medicine's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Huadong Medicine Licensing & Deal Activity
Huadong Medicine is a large biotech company based in Ireland that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Huadong Medicine ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Huadong Medicine include Solid Tumors (3 deals and trials), Immunology (2 deals and trials), CNS Disorders (2 deals and trials), and Cardiovascular (2 deals and trials). In terms of modality, Huadong Medicine has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Huadong Medicine and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Huadong Medicine's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.